ENTO missed EPS expectations by 113.16%
Oct 25, 2024, 4:33 PM
10.83%
What does ENTO do
First Wave Biopharma, headquartered in Boca Raton, Florida, develops nonsystemic therapies for gastrointestinal diseases and went public in October 2016. Its key programs include latiglutenase, capeserod, and adrulipase.
Entero Therapeutics (ENTO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Entero Therapeutics's actual EPS was -$3.37, missing the estimate of -$1.58 per share, resulting in a -113.16% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.